Release Date: March 25, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you expand on the regulatory conversation regarding the ANC threshold change from below 1,500 to below 1,000? Was this discussed before the trial initiation, and is there a risk of needing to upsize the trial? A: Dr. Paula Ragan, CEO, explained that the FDA is interested in ensuring the trial's success by focusing on moderate to severe patients. This alignment with the FDA does not impact the trial's pace, as the requirement for at least two infections per year already narrowed the patient funnel. Dr. Christophe Arbet-Engels, CMO, added that both the FDA and EMA support the approach, focusing on infection benefits rather than ANC as a non-validated biomarker.
Q: With the tightening of eligibility criteria around baseline ANC, do you expect this to slow down enrollment? A: Dr. Christophe Arbet-Engels stated that they do not expect a slowdown in enrollment as mild patients were not anticipated to represent a substantial number. The history of infections already narrowed the patient pool, and the screening process is progressing as expected.
Q: Can you provide an update on inventory levels and any early discounting trends? A: Adam Mostafa, CFO, noted that the balance sheet reflects inventory levels, which are expected to be lumpy over time based on demand. Mark Baldry, CCO, added that there is no discounting with payers at this time, maintaining a tight distribution channel through their specialty pharmacy.
Q: How many patients are currently on XOLREMDI, and was there a price increase for 2025? A: Mark Baldry stated they are not disclosing patient numbers as demand is still building. They did implement a 7% price increase at the start of 2025, which is typical for the new year.
Q: What are the commercialization goals for XOLREMDI in 2025, and how is the patient engagement strategy evolving? A: Mark Baldry explained that the focus is on building awareness and education around WHIM syndrome. They are leveraging physician experience through a peer-to-peer speaker program and pivoting to engage the patient community. The goal is to increase demand by activating both physicians and patients, with payers quickly reimbursing the product.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.